Strategic Wealth Partners Ltd. trimmed its stake in shares of Iqvia Holdings Inc (NYSE:IQV) by 47.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 325 shares of the medical research company’s stock after selling 298 shares during the quarter. Strategic Wealth Partners Ltd.’s holdings in Iqvia were worth $52,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently modified their holdings of IQV. Tower Bridge Advisors grew its stake in Iqvia by 1.1% during the second quarter. Tower Bridge Advisors now owns 108,262 shares of the medical research company’s stock worth $17,419,000 after purchasing an additional 1,157 shares during the period. Cedar Brook Financial Partners LLC acquired a new stake in Iqvia during the second quarter worth approximately $253,000. Enlightenment Research LLC acquired a new stake in Iqvia during the second quarter worth approximately $820,000. Bbva USA Bancshares Inc. grew its stake in Iqvia by 1.6% during the second quarter. Bbva USA Bancshares Inc. now owns 6,078 shares of the medical research company’s stock worth $978,000 after purchasing an additional 95 shares during the period. Finally, Manchester Capital Management LLC grew its stake in Iqvia by 1,200.0% during the second quarter. Manchester Capital Management LLC now owns 416 shares of the medical research company’s stock worth $67,000 after purchasing an additional 384 shares during the period. Institutional investors own 90.86% of the company’s stock.
In other news, insider Ari Bousbib sold 96,000 shares of the firm’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $160.00, for a total value of $15,360,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Kevin C. Knightly sold 6,945 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $158.53, for a total value of $1,100,990.85. The disclosure for this sale can be found here. Insiders sold 198,945 shares of company stock worth $30,860,991 in the last 90 days. Corporate insiders own 6.00% of the company’s stock.
Iqvia (NYSE:IQV) last posted its earnings results on Wednesday, July 24th. The medical research company reported $1.39 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.38 by $0.01. Iqvia had a return on equity of 15.95% and a net margin of 2.31%. The company had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.70 billion. During the same quarter last year, the company earned $1.29 earnings per share. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. On average, equities research analysts expect that Iqvia Holdings Inc will post 5.87 earnings per share for the current year.
Several research firms recently commented on IQV. Morgan Stanley raised their target price on Iqvia from $156.00 to $170.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 19th. Credit Suisse Group raised their price objective on Iqvia from $165.00 to $170.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. TheStreet cut Iqvia from a “b” rating to a “c+” rating in a research note on Wednesday, May 1st. Zacks Investment Research raised Iqvia from a “sell” rating to a “hold” rating in a research note on Friday, May 3rd. Finally, Stifel Nicolaus raised their price objective on Iqvia from $167.00 to $178.00 and gave the company a “buy” rating in a research note on Wednesday, June 19th. Three research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $161.13.
Iqvia Company Profile
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Story: Stochastic Momentum Index (SMI)
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.